Nuwellis: MACD Death Cross and KDJ Death Cross Triggered on 15-Minute Chart

Nuwellis's 15-minute chart has recently triggered a MACD Death Cross and KDJ Death Cross, as of August 20, 2025 at 09:45. This development indicates that the stock price may continue to decline, as the momentum of the stock price has shifted towards the downside, with the potential for further downward movement.

Nuwellis Inc. (Nasdaq: NUWE), a medical technology company specializing in fluid management solutions, has experienced a series of bearish technical indicators on its stock, as indicated by a 15-minute chart analysis. On August 13, 2025, at 15:45, the Moving Average Convergence Divergence (MACD) and the Keltner's Directional Indicator (KDJ) both triggered a death cross, signaling a potential shift in the stock's momentum towards the downside [1]. This suggests that the stock price has the potential to continue falling, with sellers currently in control of the market.

In addition to these technical indicators, Nuwellis has announced a strategic decision to exit its international operations. The company aims to concentrate exclusively on the U.S. market to capitalize on strong growth and clinical demand in cardiac surgery and pediatric programs, as well as expanding opportunities in hospital-based outpatient settings [1]. Led by CEO John Erb, Nuwellis will implement a structured wind-down of its international operations while intensifying its focus on high-acuity and hospital-based outpatient settings in the U.S. market.

The company has also postponed its Q2 2025 earnings release and conference call from August 12 to August 14, 2025. The delay is attributed to the company requiring additional time for completing valuations and allowing its auditor, Baker Tilly US, LLP, to finish related audit procedures. The rescheduled conference call will take place at 9:00 AM ET on August 14, with both webcast and dial-in options available for investors [2].

Nuwellis reported Q2 2025 financial results, with revenue declining to $1.7 million from $2.2 million in Q2 2024, primarily due to industry-wide sterilization vendor issues. The company's gross margin contracted to 55.5% from 67.2% year-over-year. Key developments include expanding to 47 pediatric centers, completing a $5 million gross capital raise, and executing a manufacturing outsourcing plan to KDI Precision Manufacturing. The company reported a net loss of $12.6 million, or $60.99 per share, compared to $7.7 million loss in Q2 2024. As of June 30, 2025, Nuwellis maintained $4.5 million in cash and remained debt-free [2].

While these developments may impact investor sentiment, it is crucial for investors to closely monitor the company's progress and earnings reports to make informed decisions.

References:
[1] https://www.stocktitan.net/news/NUWE/nuwellis-to-exit-international-operations-to-accelerate-u-s-revenue-vdi8euusdum0.html
[2] https://www.stocktitan.net/news/NUWE/nuwellis-postpones-second-quarter-2025-earnings-release-and-o1gteliquwmi.html